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Analysis and comment
Research methodology
Assessment of generalisability in trials of health
interventions: suggested framework and systematic review
C Bonell, A Oakley, J Hargreaves, V Strange, R Rees
Most evaluations of new treatments use highly selected populations, making it difficult to decide
whether they would work elsewhere. Systematic evaluation and reporting of applicability is required
Randomised trials of health interventions generally
describe outcomes among participants with little
consideration of whether the effects can be generalised.
However, generalisability cannot be assumed with either
biomedical interventions or more complex social
interventions.w1 If their results are to be translatable into
policy and practice decisions, trials must provide
evidence about how relevant the interventions might be
to other sites and populations.1 w2 Such information is
particularly crucial for resource poor settings.2
Although CONSORT criteria for reporting ran-
domised trials include assessment of generalisability,3
a framework for empirically assessing and reporting
this is lacking. We consider the factors affecting gener-
alisability using examples fromHIV and sexual health,
examine how a sample of trials looked at generalis-
ability, and suggest how to improve evaluation.
Can the intervention be delivered
elsewhere?
Several factors affect whether an intervention can be
delivered and received in other sites. Firstly, an interven-
tion must be feasible. Providers will vary in their capacity
to implement an intervention,w3 as will institutions in
being suitable places for an intervention.w4 The presence
of local “champions” may influence feasibility in a
particular site.4 Some interventions require the existence
of other health services4—for example, services for treat-
ing sexually transmitted infections require microbiology
laboratories to target the right patients. Interventions
may also require adequacy in other sectors such as
transport. Feasibility has a cost dimension: an unafford-
able intervention lacks general feasibility.
Secondly, an intervention must achieve adequate
coverage. This may depend on the overall comprehen-
siveness of health systems or on whether providers can
reach people in other ways—for example, through out-
reach. Adequate coverage may be more difficult in
some sites or sub-populations.
Finally, an intervention generally must be accept-
able to be effective. Acceptability refers to participants’
assessment of their experience of an intervention and
will influence whether recipients adhere to treatment
plans, act on health advice, or return for follow-up.4 For
example, condom promotion has proved acceptable
and subsequently effective in urban Tanzania but not in
rural regions.w5 Acceptability will vary between popula-
tions as it depends on cultural norms and can have
economic dimensions. For example, HIV voluntary
counselling and testing services that require clients to
attend clinics twice (first for testing and then for
results) may be acceptable in high income settings but
not low income settings because transport or opportu-
nity costs are too great.w3
Factors relating to delivery of an intervention are
best documented by embedding an evaluation of
process in trials.5 The study collects quantitative and
qualitative data on planning, delivery, and uptake and
how context affects them.
Does the intervention meet recipients’
needs?
To be effective an intervention must meet recipients’
needs—that is, the recipients must have capacity to
benefit from an intervention. Thus potential recipients
of an intervention should have similar needs to those of
the original study participants. Trial participants may be
untypical of the general population even in the study
site, let alone in other sites. Trials tend to under-
represent certain groups, such as minority ethnic and
low income groups, women, and older people, whose
needsmay differ from those of people included in trials.6
Trials should therefore describe the sociodemographic
profile of participants and report the extent to which
they are representative of the target population.
If the needs of future potential recipients differ
from those of the study participants, interventions may
not work in a new population or have to be adapted.
For example, provision of antiretroviral drugs in low
income countries, or to certain sub-populations may
have to be accompanied by support to promote adher-
ence in order to achieve similar outcomes to those
achieved among trial participants.w6
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This is also true of public health interventions. The
extent to which a factor contributes to the incidence
of a particular disease, and therefore needs interven-
tion, varies across populations. For example, treating
ulcerative sexually transmitted infections may have a
significant effect on HIV incidence in an HIV epidemic
localised within high risk groups but not in a more
generalised epidemic.w1 Assessing whether an interven-
tion has met recipients’ needs, or will meet those of
future recipients, requires investigators to be explicit
about the causal pathways through which an interven-
tion is expected to act and to measure relevant pathway
variables.
Current assessment of generalisability
We reviewed whether trials of HIV prevention targeting
homosexually active men explored generalisability or
factors affecting this. We obtained and examined all
available evaluation reports of eight interventions that a
recent systematic review reported to have rigorously
evaluated outcomes.7 Two reviewers independently
assessed whether the studies had empirically examined
local factors affecting feasibility, coverage, and accept-
ability; evaluated process; assessed needs; and assessed
the potential generalisability of interventions.
Six of the eight trials had integral process
evaluations,8–14 16 18 but only three of these collected
quantitative and qualitative data on the planning, deliv-
ery, and receipt of the intervention (table 1).9 12 18 Only
one process evaluation stated that consideration of
generalisability was an aim.10 Six trials gave some infor-
mation about participants’ ethnicity (usually the
proportion described as white).8 9 15–18 Seven trials
provided data on educational level.8 9 12 14–17 None
commented on the extent to which study samples were
representative of the populations being targeted.
Only those trials incorporating process evaluations
identified contextual factors influencing the feasibility,
coverage, and acceptability of their intervention (table
2). Elford et al, for example, reported that recruitment
and retention of peer educators to provide HIV
prevention in gyms was extremely difficult because of
educators’ low confidence.10
Only one study reported on needs (table 2).19
Although other studies reported baseline sexual
behaviour8 9 12 14–17 or sexual health related attitudes or
knowledge8 12 16 of the target population or partici-
pants, the purpose was to check for baseline
differences between intervention and comparison
groups rather than to describe normative need.
Most of the studies speculated about the potential
generalisability of their intervention to other sites but
did not consider this empirically. Rosser et al, for
example, wondered whether their intervention might
prove more effective among populations with more
risky sexual behaviour.17 The trials that examined con-
textual barriers and facilitators to delivering the inter-
vention could make more considered assessments of
generalisability. Two reports referred to sociological
theory to hypothesise what contextual factors might
have influenced the effect of the intervention in the
study site compared with other sites.10 12 However, these
trials both reported on interventions previously
reported as effective in other contextsw7 that were
largely ineffective in their own sites. Therefore, rather
than consider the scope for transferring the interven-
tions to new sites, they (reasonably) considered the
contextual reasons for failure of transfer.
Systematic evaluation
To make informed decisions about whether they
should implement interventions, providers require
more information than simply whether interventions
are effective in original study sites. They need informa-
tion on context and needs. However, most of the
studies we looked at did not empirically examine gen-
eralisability. Phase III trials should be judged not only
in terms of the designs and methods they use to exam-
Table 1 Interventions and process evaluation in eight studies of HIV prevention
Outcome study
Additional
process study Intervention Site
Any positive
effects? Methods of process evaluation
Stated rationale for process
evaluation
Dilley et al (2002)8 None Cognitive behavioural
HIV prevention
counselling
San Francisco
HIV clinic
Yes Adherence to treatment. Some sessions
taped but data not reported
Assess consistency,
completeness, and adherence
to intervention guidelines
Elford et al (2001)9 Elford et al (2002),10
Elford et al (2000)11
HIV peer education London gyms No Survey of men’s awareness, contact with
and perceived usefulness of work.
Interviews and group discussions with
providers and stakeholders and documents
about costs, planning, and delivery
Explore feasibility, practical
constraints, transferability,
and cultural adaptation
Flowers et al (2002)12 Flowers et al (1999)13 HIV peer education,
gay specific
genitourinary medicine
service, and telephone
advice line
Gay venues and
clinic, Glasgow
No
(intention to treat);
yes (treatment
analysis)
Observation of intervention. Survey of
men’s awareness and contact with work
and its acceptability. Provider diaries,
interviews and group discussions, and
documents about planning and delivery
None
Gold and Rosenthal
(1998)14
None Face to face HIV
prevention discussion
versus posters
Homes,
Melbourne and
Sydney
No Survey of men’s views on usefulness of
interventions
None
Imrie et al (2001)15 None Cognitive behavioural
HIV prevention
workshop
Sexual health
clinic, London
No None None
Picciano et al (2001)16 None HIV telephone
counselling
US Yes Counsellor reports of contents and
ratings of each session
None
Rosser et al (2002)17 None HIV education
seminars
US university Yes None None
Shepherd et al
(1997)18
Shepherd et al
(1999)19
HIV peer education UK homes and
other informal
sites
Yes Group discussions and interviews with
educators, including drop-outs, about
intervention training, reach, acceptability,
and delivery
To examine how peer
education can be undertaken
with gay men not yet involved
in the gay community
Analysis and comment
347BMJ VOLUME 333 12 AUGUST 2006 bmj.com
ine outcomes3 but also how they assess generalisability.
To enable this trials should:
x Include process evaluations as integral elements5
x Develop evidence based theories about how
intervention processes are influenced by contextw8 and
how processes might differ if interventions are
implemented in other sitesw9
x Report the extent to which their participants are
representative of the population being targeted6
x Describe the prevalence of the needs being met by
the intervention, informed by clear hypotheses about
the intervention’s mechanism.
We believe that these elements are essential to
comply with the existing CONSORT requirement to
report on “clinical characteristics” of participants if
clinical is interpreted as meaning need for health
intervention.
The most useful information on the potential for, as
well as the barriers to, transfer of interventions comes
from studies that compare an intervention in one site
with similar interventions provided elsewhere, as in the
study by Elford et al.10 Future phase III research might
build on such work by setting out to examine inter-
ventions implemented across diverse contexts in multi-
site studies. These would examine differential effects by
site and explore contextual determinants of success to
generate hypotheses for future research and guidelines
for the implementation of interventions outside trials.w9
This approach is compatible with a phased approach to
intervention trials. Assessing generalisability in phase III
should inform choice of sites for phase IV replicability
research.20 However, such multi-site evaluations are
unlikely unless funding for such work is increased.
Finally, systematic reviews should consider general-
isability. Currently, many do not examine intervention
process or context and do not comment on the poten-
tial for and limits to intervention effects being general-
ised to other settings and populations.w10
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Confidentiality and consent in medical research
Balancing potential risks and benefits of using
confidential data
Christina Davies, Rory Collins
Public health benefits arising from advances in medical research often rely on the use of personal
data. How can we ensure that protecting patients’ interests does not unduly hamper scientific study?
Confidential medical information is used in almost
every type of clinical and public health research. Differ-
ent research scenarios raise different practical, ethical,
and legal issues, and with these come the challenges of
balancing the potential risks associated with the use of
personal data against the potential benefits that might
be gained from the research.We consider a strategy for
explicitly reviewing the balance of these potential risks
and benefits when planning research.
Effect of current legislation
Changes in the laws on data protection1–3 have had an
important effect on training for medical research and
on the design, costs, and feasibility of research projects.
In many instances, this has improved the ways in which
personal data are handled and protected the privacy of
patients. There is, however, a general concern that
varying interpretations of current legislation are
stifling important research.4 Widespread uncertainty
among professional bodies, hospital managers, ethics
committees, clinicians, medical researchers, and the
public may be producing disproportionate obstacles to
the use of personal data when there is not genuine risk.
In some instances, interpretations of legislation
seem to have been driven less by careful consideration
of the likelihood of real harm for individuals than by
the desire to minimise the risk of criticism for
organisations.
It needs just a few such decisions to impart an extra
twist to the cycle of inefficiency in the use of public
money for medical research. Clearly, research should
conform to good practice, but it remains appropriate
to consider whether over-interpretation of data protec-
tion legislation represents another real, albeit difficult
to quantify, risk to the public.
Balancing risks and benefits
It is essential to achieve a rational view of the real risks
and benefits of research using medical records and for
any regulations to be drafted and interpreted appropri-
ately. Risks and benefits can be presented from the per-
spectives both of safeguarding the interests of the
participants in research and of pursuing the needs of
patients and the wider public for evidence on which to
base healthcare decisions.5 Individuals should not be
allowed to come to harm from research that uses infor-
mation concerning them, particularly since it may be
future patients (rather than those whose data have been
used) who benefit from such research. There is, however,
little evidence that serious harm has been caused by the
use of confidential records in medical research.4
When designing a research project using confiden-
tial data, researchers should consider the ways in which
the data are to be used and the measures to be taken to
protect confidentiality. They should assess the likelihood
of any harm being caused to individuals and the value of
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